The pharma giant upgraded full-year guidance to US$70.5-72.5bn to include better than expected contributions for the jab, which will partially be offset by R&D expenses.
The partners expect to deliver 1.6bn doses in 2021 according to the agreements secured as of mid-April.
Pfizer signed a contract to supply the inoculation to Canada and Israel beyond 2021, and is currently negotiating similar contract with other countries.
Total revenue for the US behemoth rose 8% to US$14.6bn, with reported net income up 45% to US$4.8bn. The quarterly dividend was maintained at US$0.39 per share.
Meanwhile, it is understood that the US will authorise the Pfizer/BioNTech jab for people aged 12-15, which are 16mln in the country.
Shares were flat at US$39.96 on Tuesday at open.